ROS1 and non-small cell lung carcinoma: The Kaplan-Meir curve showing time on treatment showed a non-statistical significant trend of worse outcomes with immunotherapy use versus TKI use with a median number of treatment days of 210.0 days for ROS1 positive NSCLC patients receiving TKIs (ceritinib, crizotinib, entrectinib, lorlatinib) versus median number of 70.0 days on treatment for ROS1 positive NSCLC patients receiving immunotherapy with pembrolizumab (HR = 2.766, 95% CI 0.847–9.305, p = 0.077) although the sample size was limited (Fig. 4D).